506 results on '"Thompson, E. Aubrey"'
Search Results
52. Towards Defining Morphologic Parameters of Normal Parous and Nulliparous Breast Tissues by Artificial Intelligence
53. Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
54. Additional file 1 of Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
55. Additional file 1 of Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence
56. Beta-2 adrenergic receptor gene (ADRB2) expression in HER2-positive early-stage breast cancer patients: a post-hoc analysis of the NCCTG-N9831 (Alliance) trial
57. Intestinal cell cycle regulation
58. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer
59. Cancer survivors have a lower frequency of dementia in the 95+ oldest‐old
60. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
61. Glucocorticoid regulation of rRNA synthesis
62. MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma
63. Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid
64. Glucocorticoid Inhibition of Initiation of Transcription of the DNA Encoding rRNA (rDNA) in Lymphosarcoma P1798 Cells
65. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
66. Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.
67. Abstract PS16-01: Intra-epithelial tumor immune landscapes are associated with clinical outcomes in early-stage triple-negative breast cancer
68. Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)
69. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
70. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
71. Identification of apoptotic genes mediating TGF-[beta]/Smad3-induced cell death in intestinal epithelial cells using a genomic approach
72. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
73. The path to a better biomarker:application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
74. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.
75. Gene Expression Profiling Using 3′ Tag Digital Approach
76. Cyclin D3 Is Essential for Intestinal Epithelial Cell Proliferation
77. Peroxisome Proliferator-activated Receptor γ Promotes Epithelial to Mesenchymal Transformation by Rho GTPase-dependent Activation of ERK1/2
78. Protein kinase C [beta]II and TGF[beta]RII in [omega]-3 fatty acid--mediated inhibition of colon carcinogenesis
79. SAAP-RRBS: streamlined analysis and annotation pipeline for reduced representation bisulfite sequencing
80. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines
81. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
82. Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
83. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
84. Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.
85. Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.
86. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature
87. Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy
88. Carryover effects of aromatase inhibitors in prevention
89. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
90. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma
91. TGF-β1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression
92. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages
93. Apoptosis, Glucocorticoid-Induced
94. Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells
95. Immunoreactive growth hormone production by human lymphocyte cell lines
96. A Novel Glucocorticoid Receptor Binding Element within the Murine c-myc Promoter
97. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
98. Abstract 651: Analysis of the immune microenvironment to advance breast cancer risk prediction and prevention
99. Impact of RNA Extraction and Target Capture Methods on RNA Sequencing Using Formalin-Fixed, Paraffin Embedded Tissues
100. Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.